A Phase III, Open, Randomized, Multicentric Study to Compare the Reactogenicity and Immunogenicity of GSK Biologicals' Combined Vi Polysaccharide Typhoid Vaccine and Inactivated Hepatitis A Vaccine, to That Elicited by GSK Biologicals' Hepatitis A Vaccine, Administered Singly or Concomitantly With GSK Biologicals' Vi Polysaccharide Vaccine

Trial Profile

A Phase III, Open, Randomized, Multicentric Study to Compare the Reactogenicity and Immunogenicity of GSK Biologicals' Combined Vi Polysaccharide Typhoid Vaccine and Inactivated Hepatitis A Vaccine, to That Elicited by GSK Biologicals' Hepatitis A Vaccine, Administered Singly or Concomitantly With GSK Biologicals' Vi Polysaccharide Vaccine

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2016

At a glance

  • Drugs Inactivated hepatitis A purified Vi polysaccharide typhoid vaccine (Hepatyrix) (Primary) ; Hepatitis A vaccine inactivated; Typhoid vaccine Vi-polysaccharide
  • Indications Hepatitis A; Typhoid
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 18 Nov 2011 Actual end date (Nov 2005) added as reported by ClinicalTrials.gov.
    • 18 Nov 2011 Actual initiation date (May 2002) added as reported by ClinicalTrials.gov.
    • 05 Oct 2008 Official Title amended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top